

written comments regarding the license transfer application, as provided for in 10 CFR 2.1305. The Commission will consider and, if appropriate, respond to these comments, but such comments will not otherwise constitute part of the decisional record. Comments should be submitted to the Secretary, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, Attention: Rulemakings and Adjudications Staff, and should cite the publication date and page number of this **Federal Register** notice.

For further details with respect to this action, see the application dated February 28, 2000, available for public inspection at the Commission's Public Document Room, the Gelman Building, 2120 L Street, NW., Washington, DC, and accessible electronically through the ADAMS Public Electronic Reading Room link at the NRC Web site (<http://www.nrc.gov>).

Dated at Rockville, Maryland, this 31st day of March 2000.

For the Nuclear Regulatory Commission.

**Timothy Colburn,**

*Project Manager, Section 1, Project Directorate I, Division of Licensing Project Management, Office of Nuclear Reactor Regulation.*

[FR Doc. 00-8739 Filed 4-7-00; 8:45 am]

**BILLING CODE 7590-01-P**

## **NUCLEAR REGULATORY COMMISSION**

### **Advisory Committee on the Medical Uses of Isotopes; Renewal Notice**

**AGENCY:** Nuclear Regulatory Commission.

**ACTION:** This notice is to announce the renewal of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) for a period of two years.

**SUPPLEMENTARY INFORMATION:** The U.S. Nuclear Regulatory Commission (NRC) has determined that the renewal of the charter for the Advisory Committee on the Medical Uses of Isotopes for the two year period commencing on April 4, 2000, is in the public interest, in connection with duties imposed on the Commission by law. This action is being taken in accordance with the Federal Advisory Committee Act, after consultation with the Committee Management Secretariat, General Services Administration.

The purpose of the ACMUI is to provide advice to NRC on policy and technical issues that arise in regulating the medical use of byproduct material for diagnosis and therapy. Responsibilities include providing guidance and comments on current and

proposed NRC regulations and regulatory guidance concerning medical use; evaluating certain non-routine uses of byproduct material for medical use; and evaluating training and experience of proposed authorized users. The members are involved in preliminary discussions of major issues in determining the need for changes in NRC policy and regulation to ensure the continued safe use of byproduct material. Each member provides technical assistance in his/her specific area(s) of expertise, particularly with respect to emerging technologies. Members also provide guidance as to NRC's role in relation to the responsibilities of other Federal agencies as well as of various professional organizations and boards.

Members of this Committee have demonstrated professional qualifications and expertise in both scientific and non-scientific disciplines including nuclear medicine; nuclear cardiology; radiation therapy; medical physics; radiopharmacy; State medical regulation; patient's rights and care; health care administration; medical research; medical dosimetry, and Food and Drug Administration regulation.

**FOR FURTHER INFORMATION CONTACT:** Betty Ann Torres, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555; Telephone (301) 415-0191.

Dated: April 4, 2000.

**Andrew L. Bates,**

*Federal Advisory Committee Management Officer.*

[FR Doc. 00-8738 Filed 4-7-00; 8:45 am]

**BILLING CODE 7590-01-U**

## **NUCLEAR REGULATORY COMMISSION**

### **Proposed New Appendix to Standard Review Plan (NUREG-0800), Chapter 19, "Use of Probabilistic Risk Assessment in Plant-Specific, Risk-Informed Decisionmaking: General Guidance"**

**AGENCY:** Nuclear Regulatory Commission.

**ACTION:** Notice of opportunity for public comment.

**SUMMARY:** The Nuclear Regulatory Commission (NRC) has issued for public comment a proposed new appendix to Chapter 19 of its Standard Review Plan (NUREG-0800). This chapter of the Standard Review Plan (SRP) identifies the roles and responsibilities of organizations in the NRC that participate in risk-informed reviews of

licensees' proposals for changes to the licensing basis, identifies the types of information that may be used in fulfilling an organization's review responsibilities, and provides general guidance on how the information from a probabilistic risk assessment (PRA) can be combined with other pertinent information in the process of making a regulatory decision.

The proposed appendix is titled "Appendix D—Use of Risk Information in Review of Non-Risk Informed License Amendment Requests." The appendix is being developed to provide guidance to the NRC staff on the use of risk information in those rare instances where license amendment requests appear to meet regulatory requirements but raise significant risk concerns due to some special circumstances associated with the request. The appendix is based on the guidance contained in SECY-99-246, and approved by the Commission for interim use (Staff Requirements Memorandum dated January 5, 2000.)

**DATES:** The comment period expires May 31, 2000. Comments received after this date will be considered if it is practical to do so, but the Commission is able to assure consideration only for comments received on or before this date. The NRC is also planning to hold a public meeting in Rockville, Maryland, to discuss the proposed appendix before the close of the comment period. The time and location of the meeting will be announced at a later date.

**ADDRESSES:** Written comments may be submitted to David L. Meyer, Chief, Rules and Directives Branch, Division of Administrative Services, Office of Administration, Nuclear Regulatory Commission, Washington, DC 20555-0001. Copies of comments received may be examined at the NRC Public Document Room, 2120 L Street NW. (Lower Level), Washington, DC. You may also provide comments via the NRC's website at <http://www.nrc.gov> by using the e-mail link entitled "NRCREP."

**FOR FURTHER INFORMATION CONTACT:** Mr. Robert Palla, Office of Nuclear Reactor Regulation, Mail Stop O10H4, Washington, DC, 20555-0001; telephone (301) 415-1095; e-mail: [rlp3@nrc.gov](mailto:rlp3@nrc.gov).

**SUPPLEMENTARY INFORMATION:** The guidance in the new appendix will be used by the NRC staff in its reviews of license amendment requests. The appendix is based on proposed guidance documented in SECY-99-246, "Proposed Guidelines for Applying Risk-Informed Decisionmaking in License Amendment Reviews." The Commission approved the use of this